Recent blog posts
AstraZeneca's BTK Inhibitor Acalabrutinib gets Approval for New Indications in China
Latest Hotspot
4 min read
AstraZeneca's BTK Inhibitor Acalabrutinib gets Approval for New Indications in China
3 September 2023
On September 1, 2023, the NMPA officially approved a new indication for AstraZeneca's blood cancer product, Acalabrutinib, for adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
Read →
Mabspace Biosciences initiates global Phase III clinical trials for CLDN 18.2 monoclonal antibody TST001
Latest Hotspot
3 min read
Mabspace Biosciences initiates global Phase III clinical trials for CLDN 18.2 monoclonal antibody TST001
3 September 2023
On September 1, 2023, Mabspace Biosciences registered an international multicenter Phase III clinical trial on the Drug Clinical Trial Registration and Information Publicity Platform.
Read →
Zai Lab's new drug Maqituxi Monoclonal Antibody Injection targeting HER2 has been approved in China
Latest Hotspot
4 min read
Zai Lab's new drug Maqituxi Monoclonal Antibody Injection targeting HER2 has been approved in China
3 September 2023
Margetuximab is an Fc-optimized monoclonal antibody acting on HER2, which was introduced by Zai Lab from MacroGenics.
Read →
Sirnaomics announced positive results from phase 1 clinical trials of siRNA therapy STP707
Latest Hotspot
5 min read
Sirnaomics announced positive results from phase 1 clinical trials of siRNA therapy STP707
3 September 2023
On August 31, 2023, Sirnaomics announced positive results from Phase 1 clinical trials of its RNAi therapy STP707 for treating various solid tumors.
Read →
Neurocrine's VMAT2 inhibitor Valbenazine achieves endpoint in Phase 3 clinical trial
Latest Hotspot
3 min read
Neurocrine's VMAT2 inhibitor Valbenazine achieves endpoint in Phase 3 clinical trial
3 September 2023
Recently, Neurocrine Biosciences announced new data for the VMAT2 inhibitor drug Ingrezza (valbenazine) capsules, including preliminary results from the Phase III KINECT-HD clinical trial.
Read →
Bristol-Myers Squibb’s mavacamten has announced long-term follow-up data from two phase 3 trials for the treatment of hypertrophic cardiomyopathy
Latest Hotspot
3 min read
Bristol-Myers Squibb’s mavacamten has announced long-term follow-up data from two phase 3 trials for the treatment of hypertrophic cardiomyopathy
2 September 2023
Recently, Bristol Myers Squibb has announced the latest long-term follow-up results of two Phase 3 studies that assessed the treatment efficacy of Camzyos (mavacamten).
Read →
Roche's PD-L1 monoclonal antibody, Atezolizumab subcutaneous formulation, has received approval for marketing by the UK's MHRA
Latest Hotspot
3 min read
Roche's PD-L1 monoclonal antibody, Atezolizumab subcutaneous formulation, has received approval for marketing by the UK's MHRA
2 September 2023
Recently, Roche announced that its PD-L1 targeted antibody, Tecentriq(atezolizumab), has been approved for marketing in the UK by the Medicines and Healthcare products Regulatory Agency (MHRA).
Read →
The Phase 1 clinical trial for the KRAS G12D inhibitor MRTX1133, developed by Mirati, has been launched
Latest Hotspot
4 min read
The Phase 1 clinical trial for the KRAS G12D inhibitor MRTX1133, developed by Mirati, has been launched
2 September 2023
the combined therapy of KRAS G12D inhibitor MRTX1133 and immune checkpoint inhibitors can cause sustained tumor elimination and significantly improve the survival outcomes in mice.
Read →
FibroGen's CTGF antibody Pamrevlumab failed in phase III clinical trials for DMD treatment
Latest Hotspot
3 min read
FibroGen's CTGF antibody Pamrevlumab failed in phase III clinical trials for DMD treatment
2 September 2023
On August 29, FibroGen announced that the CTGF antibody Pamrevlumab for the treatment of Duchenne Muscular Dystrophy (DMD) in the phase three LELANTOS clinical trial did not achieve its primary NSAA endpoint and crucial secondary endpoints.
Read →
First Dosing of RGX-181 in a Pediatric CLN2 Patient's Initial Clinical Results Showcased at SSIEM Yearly Symposium
Latest Hotspot
5 min read
First Dosing of RGX-181 in a Pediatric CLN2 Patient's Initial Clinical Results Showcased at SSIEM Yearly Symposium
2 September 2023
REGENXBIO Inc. shared the preliminary interim findings from a single-subject, researcher-led first-in-person study of RGX-181.
Read →
Sirnaomics Announces Successful Phase I clinical trial for STP707, a RNAi therapeutic for addressing multiple solid tumors
Latest Hotspot
4 min read
Sirnaomics Announces Successful Phase I clinical trial for STP707, a RNAi therapeutic for addressing multiple solid tumors
2 September 2023
A striking 74% of assessable patients showcased a premier response of steady disease.
Read →
Initial Dose of ISA104 Administered to First Patient with Chronic Hepatitis B in Phase 1 Human Trials
Latest Hotspot
5 min read
Initial Dose of ISA104 Administered to First Patient with Chronic Hepatitis B in Phase 1 Human Trials
2 September 2023
This inaugural human application (FIH) phase 1 examination, is exploring the efficiency of ISA104
Read →